Loading organizations...
§ Private Profile · Woburn, MA, USA
Medical device company developing and manufacturing bioactive glass orthopedic implants and bone graft substitutes for orthopedic surgery.
Key people at Bio2 Technologies.
Bio2 Technologies is a Woburn, Massachusetts-based medical device company that develops and manufactures advanced biomaterials and orthopedic implants for musculoskeletal surgery. The organization utilizes its proprietary Vitrium bioactive glass technology to produce porous bone graft substitutes that provide structural support and promote bone regeneration. Operating with an estimated 6 to 50 employees, the enterprise generates under $5 million in annual revenue and has secured less than $5 million in total Series C equity financing. The company is backed by lead investor DSM Venturing and features industry veterans Ted Bird, David Gill, and Donald W. Grimm on its board of directors. The firm has received multiple FDA clearances for its surgical devices, including cervical interbody implants and cuneiform wedges for foot and ankle applications. Bio2 Technologies was founded in 2009 by Paul Nichols and Janet Krevolin.
Key people at Bio2 Technologies.
Bio2 Technologies is a privately held medical device company based in Woburn, Massachusetts, specializing in advanced biomaterial solutions for orthopedic surgery, particularly in the musculoskeletal market.[1][2] It develops bone graft substitutes and implantable devices using proprietary CLM (Cross Linked Microstructure) technology with bioactive glass, offering high bioactivity, mechanical strength, and full resorption during bone remodeling, targeting high-growth areas like spine and foot/ankle procedures.[1][2][3] The company serves orthopedic surgeons and hospitals by providing low-cost, clinically superior alternatives to traditional implants in the $50B global orthopedic market, with products like Vitrium—a resorbable cervical interbody device that received FDA IDE approval in 2018 for clinical studies—and holds a robust IP portfolio.[1][3][4] Growth momentum includes FDA clearance for its first device in 2014, a Series C equity financing with partners like DSM Biomedical, and a small team of 9-50 employees generating under $5M in revenue.[1][2][4][5]
Bio2 Technologies emerged from innovations in biomaterials for orthopedic applications, leveraging patented CLM process technology to create strong, porous, resorbable implants from biocompatible materials like bioactive glass.[2][3] Key leaders include President and CEO Paul K. Nichols, Jr., with 38 years in medical devices, including founding three orthopedic companies with successful exits (e.g., Nexa Orthopedics acquired by Tornier in 2007); CTO Janet Krevolin, Ph.D., with 20+ years in orthopedic R&D, formerly VP at Zimmer Holdings; and other executives like Dr. Gabriele Niederauer, experienced in biomaterial commercialization.[2] Pivotal early moments include FDA clearance for its first implantable device in 2014 and IDE approval in 2018 for Vitrium's spinal fusion study, alongside Series C funding that paired the team with DSM for accelerated commercialization.[1][4] The idea stemmed from addressing limitations in existing bone grafts by enabling rapid tissue ingrowth while maintaining strength, building on in vitro and animal data.[3]
Bio2 rides the trend toward resorbable biomaterials and bioactive implants in orthopedics, addressing demand for osteostimulative devices that eliminate permanent foreign materials and enhance fusion rates amid rising musculoskeletal surgeries driven by aging populations.[1][3][4] Timing aligns with FDA's support for innovative bone grafts and a shift from autografts/allografts to synthetics, fueled by market forces like cost pressures in the $50B sector and advances in 3D-structured biomaterials.[1][3] The company influences the ecosystem by partnering with distributors and majors like DSM, accelerating adoption of fully resorbable tech that could disrupt legacy products from incumbents like Zimmer or Medtronic.[2][4]
Bio2 is poised to expand Vitrium commercialization post-clinical trials, potentially capturing share in spine fusion with its unique resorption profile amid growing minimally invasive orthopedics.[1][4] Trends like bioactive glass innovations, AI-optimized implant design, and value-based care will shape its path, possibly leading to acquisitions by strategics seeking biomaterial platforms.[2][3] Its influence may evolve from niche innovator to key supplier, tying back to its core strength: delivering superior, affordable bone regeneration in a high-stakes market.[1][4]
